By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


SEARCH JOBS








Company News
Pharmacyclics, Inc. (PCYC) Release: Supplemental New Drug Application For IMBRUVICA® Accepted By The FDA And Priority Review Granted 6/9/2014 10:51:06 AM
Pharmacyclics, Inc. (PCYC) Appoints Gregory R. Wade To Lead Business Development 5/20/2014 6:37:52 AM
Lucky Drug Made Pharmacyclics, Inc. (PCYC)' Robert Duggan A Billionaire—Can He Do It Again? 4/16/2014 8:24:34 AM
Pharmacyclics, Inc. (PCYC) Files Supplemental New Drug Application For IMBRUVICA With Phase III CLL Study Data 4/8/2014 9:25:10 AM
Pharmacyclics, Inc. (PCYC) Announces Date Of Conference Call To Discuss Financial Results For First Quarter Of 2014 4/2/2014 8:00:07 AM
Pharmacyclics, Inc. (PCYC) Reports Fourth Quarter And Full Year 2013 Results 2/21/2014 6:18:17 AM
Pharmacyclics, Inc. (PCYC) Announces Date Of Conference Call To Discuss Financial Results For Fourth Quarter And Year End 2013 2/17/2014 6:02:45 AM
Pharmacyclics, Inc. (PCYC)'s Imbruvica Wins Second Cancer Approval 2/13/2014 6:58:32 AM
Pharmacyclics, Inc. (PCYC) Release: Independent Data Monitoring Committee Recommends Phase III Study Of IMBRUVICA™ (Ibrutinib) Versus Ofatumumab Be Stopped Early Based On Statistically Significant Improvement In Progression Free Survival And Overall Survival 1/7/2014 10:59:54 AM
Pharmacyclics, Inc. (PCYC) Announces Data Presentations For Ibrutinib In B-Cell Malignancies 12/11/2013 8:54:09 AM
12345678910...
//-->